Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT02834780. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
Study identification
- NCT ID
- NCT02834780
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 128 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2016
- Primary completion
- Feb 22, 2022
- Completion
- Feb 22, 2022
- Last update posted
- Nov 12, 2023
2016 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| UC Irvine Medical Center | Orange | California | 92868-3201 | — |
| UCLA Medical Center | Santa Monica | California | 90404 | — |
| Georgetown Unversity Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Northwestern Unversity | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| John theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Duke University Cancer Center | Durham | North Carolina | 27710 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45219 | — |
| University of Pennsylsvania - Perelman Cancer Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Simmons Comprehensive Cancer Center | Dallas | Texas | 75390 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| McGuire VA Medical Center | Richmond | Virginia | 23249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02834780, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2023 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02834780 live on ClinicalTrials.gov.